Quantum BioPharma (QNTM.CN)was at last look up 1.9% in U.S. pre-market trading after saying over the Canada holiday weekend period that patient enrollment in its collaborative study with Massachusetts General Hospital (MGH) has reached the halfway mark, accompanied by "encouraging" preliminary imaging results.
The study aims to validate a positron emission tomography (PET) imaging technique that can assess demyelinated neurons with intact axons and track demyelination in patients with multiple sclerosis (MS). The first cohort of participants has been imaged. Preliminary analyses indicate "robust" signal in acute MS lesions and potential sensitivity to gray matter lesions.
If validated, this imaging approach could represent a key advancement in MS research and drug development as it would enable more precise, real-time measurement of how therapies impact myelin preservation and regeneration. Such capabilities may significantly enhance the evaluation of next-generation treatments, including Quantum's investigational candidate, Lucid-MS (Lucid-21-302).
The investigational new drug (IND) submission for Phase 2 approval for Lucid-MS was submitted to the FDA in March.
Quantum shares were last seen up US$0.12, to US$6.39 in New York Trading.